BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2 Present at 43rd Annual J.P. Morgan Healthcare Conference

San Mateo, Calif., United States:   BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to

READ MORE

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

San Mateo, Calif., United States:   5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression

READ MORE

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

Basel, Switzerland & San Mateo, Calif., United States:   New name reflects Company’s bold vision to eradicate cancer by harnessing the

READ MORE

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

San Mateo, Calif., United States:   Continued financial progress with $1 billion in quarterly total revenue, reduced GAAP loss and

READ MORE

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

San Mateo, Calif., United States:   Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with

READ MORE

BeiGene Mourns Death of Beloved Board Member Donald Glazer

San Mateo, Calif., United States:   BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to

READ MORE

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

San Mateo, Calif., United States:   BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the

READ MORE